Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 830,000 shares, representing 2.17% of the outstanding common stock for ?2,500 million. The purpose of the program is to enhance shareholder returns and capital efficiency and to implement agile capital policy in response to changes in the business environment. The program will run until March 24, 2022. As of October 31, 2021, the company had 38,268,587 shares in issue (excluding treasury shares) and 2,361,413 shares in treasury.